Monkey Anti-HIV-1 gp120 Recombinant Antibody (clone VRC07-544-LS) (CAT#: MRO-3554CQ)

Recombinant Macaque Antibody to gp120. VRC07-544-LS, a variant of human MAb VRC07 was more potent than MAbs VRC01 and VRC07 and protected macaques passively transferred with the variant prior to SHIV challenge.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
Neut

Figure 1 Structure-guided optimizations of VRC07 increase potency and breadth.

Figure 1 Structure-guided optimizations of VRC07 increase potency and breadth.

Antibodies were tested against a panel of 179 HIV-1 strains. The fraction of viruses neutralized at the given IC50 is shown. The optimized VRC07 variants (VRC07-501, VRC07-508, VRC07-523, and VRC07-544) were tested in an IgG1 format containing the FcRn binding site LS mutation. The constant region LS mutation has no effect on neutralization.

Rudicell, R. S., Kwon, Y. D., Ko, S. Y., Pegu, A., Louder, M. K., Georgiev, I. S., ... & Nabel, G. J. (2014). Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo. Journal of Virology, 88(21), 12669-12682.

IF

Figure 2 Autoreactivity of optimized VRC07 MAbs.

Figure 2 Autoreactivity of optimized VRC07 MAbs.

The reactivity of VRC07 variants to HEp-2 human epithelial cells was analyzed with an immunofluorescence cell staining assay.

Rudicell, R. S., Kwon, Y. D., Ko, S. Y., Pegu, A., Louder, M. K., Georgiev, I. S., ... & Nabel, G. J. (2014). Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo. Journal of Virology, 88(21), 12669-12682.

ELISA

Figure 3 MAb binding to cardiolipin, a mitochondrial membrane phospholipid, was assessed by ELISA.

Figure 3 MAb binding to cardiolipin, a mitochondrial membrane phospholipid, was assessed by ELISA.

VRC07 variants and 2F5 were tested at 100 μg/ml and 3-fold serial dilutions. In both assays, the optimized VRC07 variants (VRC07-501, VRC07-508, VRC07-523, and VRC07-544) were tested in an IgG1 format containing the FcRn binding site LS mutation. The constant region LS mutation does not affect autoreactivity results. OD, optical density.

Rudicell, R. S., Kwon, Y. D., Ko, S. Y., Pegu, A., Louder, M. K., Georgiev, I. S., ... & Nabel, G. J. (2014). Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo. Journal of Virology, 88(21), 12669-12682.

FuncS

Figure 4 Optimized VRC07 MAbs with the LS mutation have extended plasma half-lives.

Figure 4 Optimized VRC07 MAbs with the LS mutation have extended plasma half-lives.

VRC07-508-LS and VRC07-523-LS also had increased plasma levels and extended half-lives compared to wild-type VRC07, while VRC07-501-LS and VRC07-544-LS had pharmacokinetics similar to those of VRC07.

Rudicell, R. S., Kwon, Y. D., Ko, S. Y., Pegu, A., Louder, M. K., Georgiev, I. S., ... & Nabel, G. J. (2014). Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo. Journal of Virology, 88(21), 12669-12682.


Specifications

  • Host Species
  • Monkey
  • Type
  • Monkey IgG
  • Specificity
  • Recognizes HIV-1 gp120
  • Species Reactivity
  • HIV-1
  • Clone
  • VRC07-544-LS
  • Applications
  • Neut, IF, ELISA, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • This antibody has been reported for use in Immunofluorescence, Neutralization, Function Assay and Enzyme-Linked Immunosorbent Assay.

Target

  • Alternative Names
  • Human immunodeficiency virus type 1; HIV-1; Envelope glycoprotein GP120; gp120; HIV envelope

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone VRC07-544-LS"

See other products for "HIV-1 gp120"

Single-domain Antibody

Chimeric Antibody

CAT Product Name Application Type
MRO-135LC Anti-HIV-1 gp120 Recombinant Antibody (CAG1-51-4) ELISA, WB, Neut Chimeric antibody (mouse/human)
MRO-135LC-S(P) Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)
MRO-135LC-F(E) Anti-HIV-1 gp120 Recombinant Antibody Fab Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-4220 Rabbit Anti-HIV-1 gp120 Recombinant Antibody (clone SI299DS) WB, ELISA Rabbit IgG

Humanized Antibody

CAT Product Name Application Type
PABX-101-S(P) Human Anti-HIV-1 gp120 Recombinant Antibody (clone PG9); scFv Fragment WB, ELISA, FuncS Human scFv

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for MRO-3554CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare